Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.52 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | CTSV | O60911 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10597970 | 0.95 | RXRA (0.54) | RXRANPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4599529 | 0.90 | SMPD1 (0.54) | RXRANPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4600081 | 0.88 | RXRA (0.54) | RXRANPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL13974895 | 0.88 | RXRA (0.50) | RXRANPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL14882633 | 0.81 | CTSV (0.53) | RXRANPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4849364 | 0.80 | CA12 (0.63) | RAB9AATMCA12CA1CA2 | |
| SCHEMBL5467535 | 0.79 | PTGER1 (0.58) | RXRANPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL23536856 | 0.79 | PTGER1 (0.60) | RXRANPC1RAB9AMRGPRX4ATM | |
| SCHEMBL29212751 | 0.79 | CA12 (0.50) | NPC1HPGDRAB9ASMN1; SMN2CA12 | |
| SCHEMBL855207 | 0.78 | CTSV (0.54) | RXRANPC1HPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556034-B1 | INDOLE DERIVATIVES AS BETA-2 AGONISTS | PFIZER LTD (GB) | 2008-04-16 | — | — | EP | disclosed |
| EP-1556034-B1 | INDOLE DERIVATIVES AS BETA-2 AGONISTS | PFIZER LTD (GB) | 2008-04-16 | — | — | EP | disclosed |
| US-7138527-B2 | Inflammatory, allergic and respiratory disorders; beta 2 adrenoceptors agonists; such as 5-(-2-((-2-hydroxy-2-(4-hydroxy-3-(hydroxymethyl)phenyl)ethyl)amino)propyl) -N-(2-methoxybenzyl)-1H-indole-2-carboxamide | PFIZER INC. (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1556034-A1 | INDOLE DERIVATIVES AS BETA-2 AGONISTS | Pfizer Limited (GB) | 2005-07-27 | — | — | EP | disclosed |
| US-20050085526-A1 | Indole derivatives useful for the treatment of diseases | BROWN ALAN D (GB) | 2005-04-21 | — | — | US | disclosed |
| US-6844362-B2 | Indole derivatives useful for the treatment of diseases | PFIZER INC (US) | 2005-01-18 | — | — | US | disclosed |
| EP-1440966-A1 | Indole derivatives useful for the treatment of diseases | Pfizer Limited (GB) | 2004-07-28 | — | — | EP | disclosed |
| US-20040116503-A1 | Indole derivatives useful for the treatment of diseases | PFIZER INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004032921-A1 | INDOLE DERIVATIVES AS BETA-2 AGONISTS | PFIZER LIMITED (GB) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085526-A1 | Indole derivatives useful for the treatment of diseases | IDO1, IDO2, INMT | RXRA 3284/4885NPC1 1796/4885HPGD 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.